Ph.D. Jay R. Luly - 27 Nov 2024 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: President and CEO, Director
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Issuer symbol: ENTA
Transactions as of: 27 Nov 2024
Net transactions value: $0
Form type: 4
Filing time: 27 Nov 2024, 16:59:10 UTC
Previous filing: 14 Feb 2024
Next filing: 03 Dec 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTA	Stock Option (right to buy)	Award	$0	+250,000		$0.000000	250,000	27 Nov 2024	Common Stock	250,000	$8.83	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

Remarks:

Exhibit 24 Power of Attorney filed herewith.